Lilly’s Reyvow (lasmiditan) Receives FDA’s Approval as the First Therapy in a New Class of Acute Treatment for Migraine

Lilly's Reyvow (lasmiditan) Receives FDA’s Approval as the First Therapy in a New Class of Acute Treatment for Migraine

Shots:

  • The US FDA approval is based on P-III SAMURAI and SPARTAN, evaluated the safety and efficacy of Reyvow vs PBO for the acute treatment of migraine in adults, resulted in meeting its 1EPs of pain freedom and freedom from most bothersome symptom
  • The Reyvow will be available in retail pharmacies following its recommended controlled substance classification, currently under review by DEA and is expected within 90 days of its FDA approval
  • Reyvow (lasmiditan) targets 5-HT1F receptors, first and only approved therapy in a new class of acute treatment for migraine, with/out aura in adults and will be available in oral doses of 50 mg, 100mg & 200mg               

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Pharmaceutical Technology